Latest news with #KrishnaGupta
Yahoo
2 days ago
- Business
- Yahoo
ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics
Expected to be Effective as of Commencement of Trading on August 15, 2025 IRVINE, Calif., August 07, 2025--(BUSINESS WIRE)--ReShape Lifesciences® (Nasdaq: RSLS) announced today that its shareholders have approved all of the proposals necessary to complete the previously announced merger with Vyome Therapeutics, which is expected to be effective for the commencement of trading on Friday, August 15, 2025. The shares of common stock of the combined company are expected to commence trading on The Nasdaq Capital Market under the name Vyome Holdings, Inc. and the trading symbol "HIND." "Vyome's vision is expansive with several promising assets and we are focused on building a healthcare platform spanning the US-India innovation corridor," said Krishna Gupta, Chairman of Vyome. "We look forward to trading as a public company under the meaningful ticker symbol "HIND", which we expect to be on India's Independence Day – August 15. We have a very entrepreneurial and established board and management team, and we have a deep focus on creating value for our new and existing shareholders." "We are grateful for the overwhelming support from our shareholders for this merger with Vyome and the sale of our assets to Biorad Medisys. Vyome is well-positioned for success, and we believe this transaction offers a compelling opportunity for our shareholders as Vyome pursues its growth strategy as a Nasdaq-listed public company," said Paul Hickey, Chief Executive Officer of ReShape. Maxim Group LLC is serving as financial advisor to ReShape in connection with the transactions and Fox Rothschild LLP is acting as its legal counsel. Chardan is serving as financial advisor to Vyome for the merger and Sichenzia Ross Ference Carmel LLP is acting as its legal counsel. About ReShape Lifesciences® ReShape Lifesciences® is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit About Vyome Vyome Therapeutics is building a healthcare platform spanning the US-India innovation corridor. Vyome's immediate focus is leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. By applying groundbreaking science and its unique positioning across the US-India innovation corridor, Vyome seeks to deliver lasting value to shareholders in a hyper cost-efficient manner while upholding global standards of quality and safety. To learn more, please visit Forward-Looking Statements Certain statements contained in this document are "forward-looking statements." Examples of such statements include, but are not limited to, statements relating to the anticipated timing and completion of the proposed merger and the combined company's listing on the Nasdaq Stock Market after closing of the proposed merger. ReShape and/or the combined company may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, risks and uncertainties associated with the ability to consummate the proposed merger through the process being conducted by the parties. ReShape disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. View source version on Contacts ReShape Lifesciences Investor ContactPaul F. HickeyPresident and Chief Executive Officer949-276-7223ir@ Vyome Therapeutics ContactVyomePR@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
2 days ago
- Business
- Business Wire
ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics
IRVINE, Calif.--(BUSINESS WIRE)--ReShape Lifesciences ® (Nasdaq: RSLS) announced today that its shareholders have approved all of the proposals necessary to complete the previously announced merger with Vyome Therapeutics, which is expected to be effective for the commencement of trading on Friday, August 15, 2025. The shares of common stock of the combined company are expected to commence trading on The Nasdaq Capital Market under the name Vyome Holdings, Inc. and the trading symbol "HIND." 'Vyome's vision is expansive with several promising assets and we are focused on building a healthcare platform spanning the US-India innovation corridor,' said Krishna Gupta, Chairman of Vyome. 'We look forward to trading as a public company under the meaningful ticker symbol 'HIND', which we expect to be on India's Independence Day – August 15. We have a very entrepreneurial and established board and management team, and we have a deep focus on creating value for our new and existing shareholders.' 'We are grateful for the overwhelming support from our shareholders for this merger with Vyome and the sale of our assets to Biorad Medisys. Vyome is well-positioned for success, and we believe this transaction offers a compelling opportunity for our shareholders as Vyome pursues its growth strategy as a Nasdaq-listed public company,' said Paul Hickey, Chief Executive Officer of ReShape. Maxim Group LLC is serving as financial advisor to ReShape in connection with the transactions and Fox Rothschild LLP is acting as its legal counsel. Chardan is serving as financial advisor to Vyome for the merger and Sichenzia Ross Ference Carmel LLP is acting as its legal counsel. About ReShape Lifesciences ® ReShape Lifesciences ® is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band ® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of type 2 diabetes and metabolic disorders. The Obalon ® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit About Vyome Vyome Therapeutics is building a healthcare platform spanning the US-India innovation corridor. Vyome's immediate focus is leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. By applying groundbreaking science and its unique positioning across the US-India innovation corridor, Vyome seeks to deliver lasting value to shareholders in a hyper cost-efficient manner while upholding global standards of quality and safety. To learn more, please visit Forward-Looking Statements Certain statements contained in this document are "forward-looking statements." Examples of such statements include, but are not limited to, statements relating to the anticipated timing and completion of the proposed merger and the combined company's listing on the Nasdaq Stock Market after closing of the proposed merger. ReShape and/or the combined company may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, risks and uncertainties associated with the ability to consummate the proposed merger through the process being conducted by the parties. ReShape disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made.
Time of India
21-06-2025
- Time of India
4 cabbies held for killing youth over love affair in Lucknow
Lucknow: Madiaon police and crime branch jointly arrested four men for murder of Krishna Gupta, 26, resident of Radha Gram Duda Colony in Thakurganj for his relationship with the sister of the prime accused. All four, arrested near Madiaon flyover on Jun 20, were taxi drivers. On Jun 19, his elder brother, Suraj Gupta, filed police complaint at Madiaon police station, stating that Krishna was murdered by Sanjay Yadav alias Monu, following an altercation over Krishna being in relationship with Sanjay's sister. FIR was registered under sections 103(1), 115(2), and 351(2) of Bharatiya Nyaya Sanhita. Police arrested Monu Yadav (29) resident of Radha Gram Duda Colony, Thakurganj, originally from Ramnagar, Barabanki, along with Wasiq Khan alias Raja (21), resident of Muslimnagar, Jankipuram, originally from Muzaffarpur, Sitapur; Mohammad Aamir (23), resident of Ramleela Maidan, Madiaon, originally from Gopalpur, Sitapur and Sharif (20), resident of Sector-2 Jhopadpatti, Jankipuram, originally from Tarapur, Meerut. SHO, Madiaon, Shivanand Mishra, said the accused confessed to the crime. "The accused invited Krishna to drink with them and murdered him with a heavy iron rod, a wrench (pana) and blades. His body was dumped near Ghailla Bridge. Police recovered the blood-stained iron rod and wrench used in the murder," said Mishra. Police said items seized from crime scene include a wallet, passbook and Aadhaar and PAN cards of Krishna the deceased. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Giao dịch vàng CFDs với sàn môi giới tin cậy IC Markets Tìm hiểu thêm Undo Three mobile phones, Rs 270 cash and two vehicles were seized under Section 207 of Motor Vehicles Act. The body was found on June 20 with fatal injuries on the neck, head and face. Following investigation, police added Section 3(5)/238 of the BNS to the charges. Officials ensured compliance with Supreme Court and Human Rights Commission guidelines during arrest. Accused were presented before court and verification of their criminal backgrounds is underway across other districts and police stations.
